PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩0 per share · Prices as of the 2026-10-02 close
Xplus is attempting to expand beyond its loss-making mobile accessory core into new B2C businesses such as cosmetics, but frequent changes in its controlling shareholder and an overhang of unconverted convertible bonds remain concurrent issues.
The company posted operating losses in all four years from 2022 to 2025, with 2025 revenue of KRW 10.08 billion slightly down from KRW 10.43 billion in 2024.
Quarterly net income has swung sharply, from a net loss of KRW 5.48 billion in Q3 2025 to a net profit of KRW 4.88 billion in Q4 2025.
The core business supplies IP-licensed smart accessories using Disney and Kakao intellectual property to Samsung Electronics on a B2B basis.
In 2025 the company prepared a cosmetics (Egg Cosmetics) B2C business through subsidiaries and aims for a meaningful earnings contribution starting in 2026.
The controlling shareholder has changed multiple times over roughly the past year, and KRW 11.14 billion of the 4th-series convertible bond remains unconverted at a conversion price of KRW 3,011, keeping dilution risk in play.
Xplus manufactures and sells wearable IT accessories such as device covers, wireless chargers, and earphone cases, having changed its name from Hain Korea to the current name in 2024.
The company listed on KOSDAQ through a SPAC merger, and its core competitive edge lies in supplying IP-themed IT device accessories secured through a licensing agreement with The Walt Disney Company Korea and collaboration with Kakao.
Its flagship 'smart cover' product syncs with smartphones so that home-screen themes and icons change accordingly, and it is supplied to Samsung Electronics on a business-to-business basis.
Starting in 2025 the company completed a portfolio restructuring and, through subsidiaries Signal Wave and Egg Clinic, prepared an 'Egg Cosmetics' dermocosmetic business. That cosmetics line planned a new product launch in April and intends to use it to expand distribution and diversify its product portfolio.
Management has stated that from 2026 it will roll out IP-linked promotions in earnest and diversify into cosmetics, food, and other B2C products and distribution channels to pursue top-line growth.
The mobile accessory market itself has low entry barriers and features many competing manufacturers and distributors, with recurring distribution-cost burdens such as sales commissions.
On the governance side, the controlling shareholder has shifted repeatedly from the founder to various investment partnerships, raising recurring concerns about business continuity.
| Quarter | Revenue | Operating profit | Op. margin |
|---|---|---|---|
| 2025Q2 | ₩2.5B | -₩1.7B | −68.2% |
| 2025Q3 | ₩5B | -₩800M | −15.0% |
| 2025Q4 | ₩1.4B | -₩2.2B | −161.2% |
| 2026Q1 | ₩3.9B | -₩1.1B | −27.4% |
| 2026Q2 | ₩2.7B | -₩2.3B | −86.1% |
| Year | Revenue | Operating profit | Net income (parent) | Op. margin | ROE | Debt-to-equity |
|---|---|---|---|---|---|---|
| 2022 | ₩16.5B | -₩77,049,104 | -₩4.5B | −0.5% | −31.1% | 101.5% |
| 2023 | ₩9.8B | -₩3.7B | -₩8.6B | −37.9% | −170.5% | 555.8% |
| 2024 | ₩10.4B | -₩3.9B | -₩2.1B | −37.3% | −20.0% | 139.6% |
| 2025 | ₩10.1B | -₩5.2B | -₩2.3B | −51.2% | −11.1% | 176.7% |
Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-08-23
Annual revenue fell sharply from KRW 16.49 billion in 2022 to KRW 9.78 billion in 2023, then stayed in a roughly KRW 10 billion range at KRW 10.43 billion in 2024 and KRW 10.08 billion in 2025.
Operating losses widened from KRW 0.08 billion in 2022 to KRW 3.70 billion in 2023, KRW 3.89 billion in 2024, and KRW 5.16 billion in 2025, pushing the operating margin down to -51.2% in 2025.
Net income attributable to owners deteriorated sharply to a loss of KRW 4.52 billion in 2022 and KRW 8.55 billion in 2023, before narrowing to losses of KRW 2.11 billion in 2024 and KRW 2.29 billion in 2025.
On a quarterly basis, revenue of KRW 5.02 billion in Q3 2025 (operating loss of KRW 0.75 billion, net loss of KRW 5.48 billion) fell sharply to KRW 1.38 billion in Q4 2025 (operating loss of KRW 2.22 billion), yet net income swung to a profit of KRW 4.88 billion, which appears attributable to a non-operating, one-off item.
Into 2026, quarterly net losses widened again, with revenue of KRW 3.93 billion (operating loss KRW 1.08 billion, net loss KRW 3.39 billion) in Q1 and KRW 2.66 billion (operating loss KRW 2.29 billion, net loss KRW 3.87 billion) in Q2.
Total equity shrank to KRW 5.01 billion in 2023 before recovering to KRW 10.55 billion in 2024 and KRW 20.69 billion in 2025 following capital raises, while total liabilities also grew to KRW 36.56 billion in 2025, lifting the debt ratio to 176.7%.
Operating cash flow was negative in all four years, with the outflow expanding notably to KRW 15.12 billion in 2025. Overall, the pattern combines stagnant revenue, widening operating losses, and large quarter-to-quarter swings in net income.
The mobile IT accessory market has matured alongside slowing smartphone penetration growth, and it remains a low-entry-barrier segment with many small and mid-sized manufacturers and distributors competing.
Within this market, Xplus has sought differentiation not through its own brand but through character-IP licensed products tied to Disney and Kakao and B2B supply to Samsung Electronics.
As of Q3 2024, mobile accessory export-related revenue rose 127.7% year over year, yet rising sales commissions and other distribution costs widened the operating loss at the same time, illustrating that revenue growth has not translated directly into improved profitability.
The dermocosmetic market the company has newly entered is likewise crowded with numerous brands and features intense competition for distribution and marketing, meaning that building initial brand recognition and securing channels will be critical for a new entrant.
With the accessory business's stagnant scale overlapping the early stage of the cosmetics and other new ventures, the company as a whole appears to be in a transitional phase of business-model conversion rather than a clear growth cycle.
Given the absence of a pronounced scale advantage or proprietary brand strength relative to peers, maintaining IP licensing relationships and B2B trading partners remains a key variable for future positioning.
The company has characterized 2025 as a preparatory year for business restructuring and stated that from 2026 it will pursue full-scale top-line growth through IP-linked promotions and an expanded lineup of B2C products such as cosmetics and food.
The cosmetics subsidiary (Egg Cosmetics) plans a new product launch alongside its existing dermocosmetic line and intends to expand distribution.
On the funding side, a KRW 18 billion third-party allotment capital raise was completed in May 2026, adding 1,550,775 new shares and bringing total shares outstanding to 25,043,237.
Around the same time, the par value per share was consolidated from KRW 100 to KRW 500 (a 5-for-1 consolidation), which also reset the capital-raise issue price from KRW 516 to KRW 2,580.
However, KRW 11.14 billion of the 4th-series convertible bond remained unconverted as of the relevant filing date at a conversion price of KRW 3,011, meaning further dilution could occur if additional conversion claims are made.
The controlling shareholder composition has also changed multiple times over roughly the past year, accompanied by management turnover, making the stability of governance underpinning execution of the new businesses a key point to watch.
Beyond the company's own disclosures, no brokerage price targets or earnings estimates were identified in the sources reviewed.
The company has posted net losses in each of the past four years, putting it in a range where the price-to-earnings ratio is not meaningfully calculable. The stock trades at a level that carries a premium to net asset value, rather than at a discount to book value.
No dividend payment has been identified in recent disclosures, so there is no dividend-yield reference point to draw on. Total equity has expanded step by step from its 2023 low through capital raises, even as net income has remained in loss territory.
The market capitalization itself is small, which is also worth factoring into any valuation interpretation given the potential for greater liquidity and price variability.
PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-08-23
The company completed a business restructuring in 2025 and plans a meaningful earnings contribution from B2C product lines such as Egg Cosmetics starting in 2026. Adding new consumer-goods lines on top of the existing mobile accessory business could diversify the consolidated revenue structure.
That said, the new business is still at an early stage and its actual revenue contribution has not yet been confirmed.
The IP secured through a licensing agreement with The Walt Disney Company Korea and collaboration with Kakao serves as a product differentiator in the absence of strong proprietary brand equity. The B2B relationship supplying smart covers to Samsung Electronics has also been maintained. These licensing and trading relationships can function as a barrier relative to new entrants.
After total equity contracted sharply in 2023, it recovered step by step through capital raises up to 2025. In May 2026, a KRW 18 billion third-party allotment raise further reinforced operating funds. However, it should also be considered that this process is accompanied by equity dilution.
Over roughly the past year, the controlling shareholder has changed multiple times, shifting from the founder to various investment partnerships, with the CEO also changing in the process.
Concerns have been raised that a controlling shareholder in the form of an investment partnership may have limited capacity for professional management engagement to support business expansion. This governance volatility adds to uncertainty around the execution of new businesses.
From 2022 through 2025, revenue merely fluctuated between roughly KRW 10 billion and KRW 16.5 billion without a clear growth trajectory, while the operating loss actually widened. The 2025 operating margin of -51.2% deteriorated from -37.3% in the prior year. Operating cash flow was also negative in all four years, indicating weak cash-generation capacity.
As of the relevant filing date, KRW 11.14 billion of the 4th-series convertible bond remained unconverted, with a conversion price of KRW 3,011. Further conversion claims going forward would increase the share count and dilute existing shareholders.
The company also has a history of repeated bonus issues, rights offerings, and CB conversions that have significantly altered its share count multiple times in the past.
The controlling shareholder has changed multiple times within a short period, with the most recent controlling-shareholder change disclosure occurring in May 2026.
Whether a controlling shareholder in the form of an investment partnership can consistently pursue a long-term business strategy has not yet been demonstrated. Repeated changes in control raise the possibility of disruption to the execution of new businesses.
The debt ratio surged to 555.8% in 2023 before easing to 176.7% in 2025, yet it remains elevated. Operating cash flow was negative in all four years, indicating heavy reliance on external funding. If further rights issues or convertible bond issuances follow, repeated shareholder-value dilution could occur.
The cosmetics business only organized its structure, distribution, and operating processes in 2025 and remains at an early stage that has not yet been validated by results.
The dermocosmetic market is one where many established brands compete, and building channel access and brand recognition as a new entrant may take time. There is also a possibility that the planned new product launch and distribution expansion could be delayed or fall short of expectations.
The Q3 2026 (July-September) quarterly report is due for disclosure. This is a point to check whether revenue recovers and whether the operating loss narrows.
It will be worth checking whether the Egg Cosmetics distribution expansion and B2C revenue contribution actually materialize.
Continued monitoring is needed on whether additional conversion claims are made against the remaining KRW 11.14 billion 4th-series convertible bond (conversion price KRW 3,011) and the resulting scale of dilution.
The 2026 annual business report is due for disclosure. This is a point to check confirmed full-year results and the audit opinion.
Xplus has stated that, amid stagnant revenue and widening operating losses in its core mobile accessory business, it intends to make 2026 the year new B2C businesses such as cosmetics begin contributing meaningfully to results.
Financially, the company has recorded net losses for four consecutive years alongside negative operating cash flow, and while total equity has recovered step by step through capital raises, that process has come with accompanying equity dilution.
On the governance front, the controlling shareholder has changed multiple times over roughly the past year, with related disclosures continuing as recently as May 2026, leaving uncertainty around management continuity.
The unconverted balance of the 4th-series convertible bond and the possibility of further fundraising are additional variables worth watching from a shareholder-value perspective.
On the other hand, the Disney and Kakao IP licenses, the Samsung Electronics supply relationship, and the early-stage preparation of the new cosmetics business are cited as grounds for business diversification.
Investors will want to track upcoming quarterly results, the actual revenue contribution of new businesses, progress on convertible bond conversion, and any further governance-related disclosures.
Report written 2026-09-05 · Data as of 2026-09-04
This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.